alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo.
Sialic acids on vertebrate cell surfaces mediate many biological roles. Altered expression of certain sialic acid types or their linkages can have prognostic significance in human cancer. A classic but unexplained example is enhanced alpha2-6-sialylation on N-glycans resulting from overexpression of the Golgi enzyme beta-galactoside:alpha2-6-sialyltransferase (ST6Gal-I). Previous data supporting a role for the resulting Sia alpha 2-3Gal beta 1-4GlcNAc (Sia6LacNAc) structure in tumor biology were based on in vitro studies in transfected carcinoma cells, in which increased Sia6LacNAc on beta1-integrins enhanced their binding to ligands, and stimulated cell motility. Here, we examine for the first time the in vivo role of the ST6Gal-I enzyme in the growth and differentiation of spontaneous mammary cancers in mice transgenic for a mouse mammary tumor virus promoter-driven polyomavirus middle T antigen, a tumor in which beta1-integrin function is important for tumorigenesis and in maintaining the proliferative state of tumor cells. Tumors induced in St6gal1-null animals were more differentiated compared with those in the wild-type background, both by histologic analysis and by protein expression profiles. Furthermore, we show the St6gal1-null tumors have selectively altered expression of genes associated with focal adhesion signaling and have decreased phosphorylation of focal adhesion kinase, a downstream target of beta1-integrins. This first in vivo evidence for a role of ST6Gal-I in tumor progression was confirmed using a novel approach, which conditionally restored St6gal1 in cell lines derived from the null tumors. These findings indicate a role for ST6Gal-I as a mediator of tumor progression, with its expression causing a less differentiated phenotype, via enhanced beta1-integrin function.
Hedlund
Maria
M
Glycobiology Research and Training Center, Department of Medicine, University of California, San Diego, La Jolla, California 92093-0687, USA.
Ng
Elisa
E
Varki
Ajit
A
Varki
Nissi M
NM
D000818:Animals; D002277:Carcinoma / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D002454:Cell Differentiation; D018450:Disease Progression; D005260:Female; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D019012:Integrin beta1 / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008954:Models, Biological; D011134:Polysaccharides / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology; D012794:Sialic Acids / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D012799:Sialyltransferases / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics; D014407:Tumor Cells, Cultured; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase
D019012:Integrin beta1; D011134:Polysaccharides; D012794:Sialic Acids; D012799:Sialyltransferases; D051417:Focal Adhesion Kinase 1; C496051:Ptk2 protein, mouse; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase